Navigation Links
Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results
Date:3/13/2008

utely inflamed areas, nor used to reduce the swelling of bites or stings. Hyaluronidase should not be used for intravenous injections because the enzyme is rapidly inactivated. Furosemide, the benzodiazepines, and phenytoin are incompatible with hyaluronidase. Please see accompanying package insert at http://www.hylenex.com for full Prescribing Information.

About Halozyme Therapeutics, Inc.

Halozyme is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the drug delivery, oncology and dermatology markets. The company's portfolio of products and product candidates is based on intellectual property covering the family of human enzymes known as hyaluronidases. The company's Enhanze(TM) Technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. Its key partnerships are with Roche to apply Enhanze Technology to Roche's biological therapeutic compounds for up to 13 targets and with Baxter to apply Enhanze Technology to Baxter's biological therapeutic compound, GAMMAGARD LIQUID 10%. In addition, the company has received FDA approval for two products: Cumulase(R), for use in in-vitro fertilization, and HYLENEX, for use as an adjuvant to increase the absorption and dispersion of other injected drugs and fluids. HYLENEX is partnered with Baxter International Inc. The Company also has a number of different enzymes in its portfolio that are targeting significant areas of unmet need.

Safe Harbor Statement

In addition to historical information, the statements set forth above include forward-looking statements (including, without limitation, (i) statements concerning the company's ability to execute on its strategy and (ii) clinical trial results and the conclusions drawn from such trials) that involve risk and uncertainties that could cause actual results to differ materially from those in the forw
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Baxter and Halozyme Announce Collaboration for Development of Subcutaneous GAMMAGARD LIQUID(TM) Administration Using Enhanze(TM) Technology
2. Halozyme Therapeutics to Present at UBS 2007 Global Life Sciences Conference
3. Halozyme Therapeutics Reports 2007 Third Quarter Financial Results
4. Halozyme Therapeutics Amends Stockholder Rights Plan
5. Halozyme Therapeutics to Present at the BIO CEO and Investor Conference and the Roth Growth Stock Conference
6. Halozyme Therapeutics to Hold Pipeline Update Conference Call on March 14
7. Halozyme Therapeutics Presents Favorable New Safety and Pharmacokinetic Data on rHuPH20 Enzyme Produced Via New Manufacturing Process at European Federation for Pharmaceutical Sciences
8. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
9. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
10. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
11. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 23, 2014 Nashville Fertility Center announced ... treasurer for the American Society for Reproductive Medicine (ASRM), ... research in reproductive medicine. In his new role ... the executive board and will have a voice in ... has actively supported ASRM since 1984 when he joined ...
(Date:12/24/2014)... BEIJING , Dec. 23, 2014 ... or the "Company"), a leading fully integrated plasma-based ... today announced that its majority-owned subsidiary, Shandong Taibang ... Practices ("GMP") certification from the China Food and ... factor production facility. As previously disclosed in the ...
(Date:12/24/2014)... Dec. 23, 2014 Sigma-Aldrich Corporation (NASDAQ: ... waiting period under the Hart-Scott-Rodino Antitrust Improvements Act ... on December 22, 2014, thereby completing the U.S. ... the acquisition of the Company by Merck KGaA, ... satisfies another condition to closing the transaction, which ...
(Date:12/22/2014)... 2014 The Center for Professional ... technical training across the life sciences industry, has partnered ... (SCDM) to provide the organization's members with discounted classroom ... to the more than 350 sessions across 80 course ... off when registering for a public course ...
Breaking Biology Technology:Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 3China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3CfPIE Announces Partnership with the Society for Clinical Data Management 2CfPIE Announces Partnership with the Society for Clinical Data Management 3
... MONTREUX, Switzerland, Feb. 4 Patients with frequently,relapsing ... time to an,initial relapse when risperidone long-acting injection ... new study. The study compared,patients who received RLAI ... combined with placebo., The study was presented ...
... CARLSBAD, Calif., Feb. 4 Ardea Biosciences,Inc. (Nasdaq: ... virus (HIV) Scientific Advisory Board (SAB) with the,appointment of ... SAB will,provide independent scientific advice and counsel to the ... to treat HIV., "Establishing a strong scientific advisory ...
... MINNEAPOLIS, Feb. 4 Uroplasty, Inc. (Amex:,UPI) announced ... the third,quarter of fiscal 2008 ended December 31, ... 2008. The Company will host a conference call ... at 10:00 a.m. Central,Time. David Kaysen, President and ...
Cached Biology Technology:Study Suggests Risperidone Long-Acting Injection Combined with Standard Treatment Helped Delay Time to Relapse in Patients with Bipolar Disorder 2Study Suggests Risperidone Long-Acting Injection Combined with Standard Treatment Helped Delay Time to Relapse in Patients with Bipolar Disorder 3Study Suggests Risperidone Long-Acting Injection Combined with Standard Treatment Helped Delay Time to Relapse in Patients with Bipolar Disorder 4Study Suggests Risperidone Long-Acting Injection Combined with Standard Treatment Helped Delay Time to Relapse in Patients with Bipolar Disorder 5Ardea Biosciences Establishes Scientific Advisory Board for HIV Program 2Ardea Biosciences Establishes Scientific Advisory Board for HIV Program 3Ardea Biosciences Establishes Scientific Advisory Board for HIV Program 4
(Date:12/11/2014)... Dec. 10, 2014  That blood pressure plays a role ... Hypertension – the medical term for high blood pressure – ... and the inflatable cuff that,s used in measuring blood pressure ... there,s nothing new about hypertension, its triggers and its effects. ... the condition and the best ways to treat it. ...
(Date:12/10/2014)... 2014  Valencell, a leader in performance biometric data ... demand from its licensees for highly accurate, clinically validated ... solely coming from fitness and health sectors, but first ... wearable is only as useful as the biometric data ... driver in long-term mass consumer adoption of wearable products," ...
(Date:12/10/2014)... Research and Markets ( http://www.researchandmarkets.com/research/xclcvw/biometrics_market ... "Biometrics Market in Japan 2014-2018" report to ... The integration of biometrics and ... and upgradation of the driver,s license is one ... Besides the aforementioned projects, biometrics is being used ...
Breaking Biology News(10 mins):Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Wearable Technology Products Demand Highly Accurate Biometric Technology 2Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2
... new study seeks to determine how one parasitic species can ... The human body louse ( Pediculus humanus ) can transmit ... (also Pediculus humanus ) does not. A report ... Molecular Biology . "Body louse-transmitted diseases include trench fever, ...
... authors describe how in laboratory tests, they compared the ... stress by several antioxidants, some of which are found ... sunburn, UVA radiation penetrates deeper, damaging our DNA by ... skin its elastic quality. The Newcastle team found ...
... New research co-written by University of Montana scientists finds ... 31 large carnivore species. The analysis, published Jan. 9 in ... species including tiger, lion, dingo and puma are ... and John J. Craighead Chair and Professor of Wildlife Conservation ...
Cached Biology News:1 species, 2 outcomes: Team seeks source of body louse pathology 2Fresh faced: Looking younger for longer 2Fresh faced: Looking younger for longer 3Study shows large carnivore numbers and range declining worldwide 2
carnitine deficiency-associated gene expressed in ventricle 1...
HSV 1 IgG...
... R&D Systems adds two new Stem Cell ... stem cell products. The Human Embryonic Stem ... contains the antibodies against: alkaline phosphatase, Nanog, ... Stem Cell Marker Antibody Panel Plus (Catalog ...
... Printing Kit contains choice of Printing Surface (3 glass ... Ti adhesion layer, 1 silicon wafer coated with 1000 ... plain glass slides), PDMS Stamps (3 PDMS micropatterned stamps ... 100 um x 10 mm or 200 um x ...
Biology Products: